Tango Therapeutics, Inc. (TNGX)

Real-time intraday values

Market Overview

From:

To:

TNGX Intraday

No data available

SymbolTNGX

IPO DateSep 3, 2020

CEODr. Barbara L. Weber M.D.

Full Time Employees137

SectorHealthcare

IndustryBiotechnology

CountryUnited States

ExchangeNasdaqGM

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Performance

Period	Return %	Value Change
1 Day	+34.12%	+6.90 US$
5 Days	+26.32%	+5.65 US$
1 Month	+17.81%	+4.10 US$
6 Months	+197.37%	+18.00 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of TNGX...

Key Statistics

Market Cap

3.92B

P/E Ratio

N/A

Div Yield

N/A

52W High

$30.01

52W Low

$3.12

Analyst Consensus

ConsensusStrong Buy

Bullish975.0%

Neutral325.0%

Bearish00.0%

52W Analyst Price Targets

Min Target
$21.00

Max Target
$55.00

Current$27.12

Avg Target$31.90

Analyst Recommendations

Target Price:$31.90($21.00 - $55.00)

Firm	Rating	Target Price	Upside Potential	Date
Mizuho	Outperform	$30.00	+10.62%	5/15/2026
Piper Sandler	Neutral	$24.00	-11.50%	5/15/2026
Jefferies	Hold	$27.00	-0.44%	5/14/2026
Leerink Partners	Outperform	$55.00	+102.80%	5/14/2026
Wedbush	Outperform	$33.00	+21.68%	5/14/2026
Stifel	Buy	$40.00	+47.49%	4/27/2026
Canaccord Genuity	Buy	$30.00	+10.62%	4/2/2026
Mizuho	Outperform	$20.00	-26.25%	3/11/2026
Stifel	Buy	$24.00	-11.50%	3/9/2026
Wedbush	Outperform	$19.00	-29.94%	3/6/2026